Wan-Jen Hong

Wan-Jen Hong, M.D., is the Senior Vice President of Clinical Development at Prelude Therapeutics. Dr. Hong is a physician-scientist with more than 10 years of clinical and scientific expertise in hematology and oncology disorders. Prior to joining Prelude, most recently, she was Chief Medical Officer at Imago Therapeutics, where she was responsible for leading the clinical development for a late-stage asset in myeloproliferative neoplasms. She previously spent seven years at Genentech where she was a Group Medical Director. At Genentech, Dr. Hong worked on the development of several molecules across multiple indications in hematology and oncology and played a leading role in the indication expansion of venetoclax (VENCLEXTA®) in acute myeloid leukemia. She earned a bachelor’s degree in chemical engineering and biology from the Massachusetts Institute of Technology and completed both her medical doctorate and clinical training, including a hematology/oncology fellowship, at Stanford University. She is also currently an Adjunct Clinical Assistant Professor, the Department of Medicine-Hematology at Stanford University, School of Medicine.